Evidence
Provider and Study Source Ledger
Every published claim resolves to a record here: the source, who captured it, when, and what state it is in now.
Direct answer
The source ledger is the backing record for every figure on this site. Each entry holds the claim, the source title and URL, the source type, the capture date, the reviewer, an archive reference, the evidence strength and a next-review date. Clicking any provenance stamp on any page opens the matching entry.
| ID | Claim | Source | Captured | Status |
|---|---|---|---|---|
| EV-0101 | SURMOUNT-1 reported mean weight reductions of 16.0%, 21.4% and 22.5% at 72 weeks versus 2.4% with placebo | Tirzepatide Once Weekly for the Treatment of Obesity | 2026-07-24 | Verified |
| EV-0102 | SURMOUNT-5 reported −20.2% weight change with tirzepatide versus −13.7% with semaglutide at 72 weeks | Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | 2026-07-24 | Verified |
| EV-0103 | SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, weight, hypoxic burden, hsCRP and systolic blood pressure | Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity | 2026-07-24 | Verified |
| EV-0104 | Three years of tirzepatide in obesity with prediabetes markedly lowered progression to type 2 diabetes versus placebo | Tirzepatide for Obesity Treatment and Diabetes Prevention | 2026-07-24 | Verified |
| EV-0105 | SURMOUNT-4 examined continued tirzepatide versus withdrawal for maintenance of weight reduction | Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial | 2026-07-24 | Verified |
| EV-0201 | FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need | FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List | 2026-07-24 | Verified |
| EV-0202 | The formal notice appeared at 91 Fed. Reg. 23431 on 1 May 2026, docket 2026-08552 | List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B | 2026-07-24 | Verified |
| EV-0203 | FDA extended the comment period; comments must be submitted by 30 July 2026 | Comment period extension, List of Bulk Drug Substances Under Section 503B | 2026-07-24 | Verified |
| EV-0301 | NexLife (opens nexlife.us in a new tab) publishes tirzepatide (standard subcutaneous) at $215/month on the month-to-month plan, $215 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife (opens nexlife.us in a new tab) — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0302 | NexLife (opens nexlife.us in a new tab) publishes tirzepatide (standard subcutaneous) at $195/month on the 3-month prepaid plan, $585 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife (opens nexlife.us in a new tab) — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0303 | NexLife (opens nexlife.us in a new tab) publishes tirzepatide (standard subcutaneous) at $190/month on the 6-month prepaid plan, $1140 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife (opens nexlife.us in a new tab) — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0304 | NexLife publishes tirzepatide (standard subcutaneous) at $186/month on the 12-month prepaid plan, $2232 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0305 | NexLife publishes semaglutide (standard subcutaneous) at $165/month on the month-to-month plan, $165 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | never | Provider-reported |
| EV-0306 | NexLife publishes semaglutide (standard subcutaneous) at $149/month on the 3-month prepaid plan, $447 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | never | Provider-reported |
| EV-0307 | NexLife publishes semaglutide (standard subcutaneous) at $147/month on the 6-month prepaid plan, $882 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | never | Provider-reported |
| EV-0308 | NexLife publishes semaglutide (standard subcutaneous) at $145/month on the 12-month prepaid plan, $1740 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0309 | NexLife publishes tirzepatide (microdose) at $189/month on the month-to-month plan, $189 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0310 | NexLife publishes tirzepatide (microdose) at $159/month on the 3-month prepaid plan, $479 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0311 | NexLife publishes tirzepatide (microdose) at $150/month on the 6-month prepaid plan, $899 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0312 | NexLife publishes tirzepatide (microdose) at $147/month on the 12-month prepaid plan, $1764 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0313 | NexLife publishes semaglutide (microdose) at $129/month on the month-to-month plan, $129 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0314 | NexLife publishes semaglutide (microdose) at $117/month on the 3-month prepaid plan, $357 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0315 | NexLife publishes semaglutide (microdose) at $114/month on the 6-month prepaid plan, $684 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0316 | NexLife publishes semaglutide (microdose) at $110/month on the 12-month prepaid plan, $1320 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0317 | NexLife publishes tirzepatide (sublingual ODT) at $229/month on the month-to-month plan, $229 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0318 | NexLife publishes tirzepatide (sublingual ODT) at $219/month on the 3-month prepaid plan, $657 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0319 | NexLife publishes tirzepatide (sublingual ODT) at $205/month on the 6-month prepaid plan, $1230 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0320 | NexLife publishes tirzepatide (sublingual ODT) at $199/month on the 12-month prepaid plan, $2388 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0321 | NexLife publishes semaglutide (sublingual ODT) at $199/month on the month-to-month plan, $199 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0322 | NexLife publishes semaglutide (sublingual ODT) at $185/month on the 3-month prepaid plan, $597 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0323 | NexLife publishes semaglutide (sublingual ODT) at $177/month on the 6-month prepaid plan, $1062 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0324 | NexLife publishes semaglutide (sublingual ODT) at $165/month on the 12-month prepaid plan, $1980 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0350 | NexLife states it is LegitScript-certified | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0351 | NexLife states it works exclusively with LegitScript-certified, NABP-accredited pharmacies | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0352 | NexLife states every batch undergoes independent third-party testing for potency, sterility, pH and endotoxin | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0353 | NexLife states compounded medication is prepared by U.S.-licensed 503A compounding pharmacies | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0354 | NexLife states availability in all 50 states | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0355 | NexLife cites SURMOUNT-1 as showing average weight loss of up to 24.3% over 72 weeks | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0356 | NexLife references self-reported outcomes from 518 members | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0106 | SUMMIT reported a 38% reduction in the combined endpoint of death and worsening heart-failure events in obesity-related HFpEF | Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy | 2026-07-24 | Verified |
| EV-0107 | Retatrutide phase 3 figures circulating in commercial secondary sources are unconfirmed against a primary publication | Retatrutide phase 2 trial | 2026-07-24 | Provider-reported |
| EV-04001 | Found lists tirzepatide (compounded injectable) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04002 | NexLife lists tirzepatide (compounded injectable) at $186 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04003 | Oak Longevity lists tirzepatide (compounded injectable) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | third_party |
| EV-04004 | Shed lists tirzepatide (compounded injectable) at $245 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04005 | Mochi Health lists tirzepatide (compounded injectable) at $278 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04006 | Enhance.MD lists tirzepatide (compounded injectable) at $280 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04007 | Eden lists tirzepatide (compounded injectable) at $298 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04008 | Noom Med lists tirzepatide (compounded injectable) at $299 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04009 | TrimRx lists tirzepatide (compounded injectable) at $349 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04010 | MEDVi lists tirzepatide (compounded injectable) at $399 per month, total including any required membership | Provider pricing dataset, July 2026 | never | Verification pending |
| EV-04011 | bmiMD lists tirzepatide (compounded injectable) at $399 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04012 | NexLife lists tirzepatide (compounded microdose) at $147 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04013 | Enhance.MD lists tirzepatide (compounded microdose) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04014 | Shed lists tirzepatide (compounded microdose) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04015 | bmiMD lists tirzepatide (compounded microdose) at $349 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04016 | NexLife lists tirzepatide (compounded oral / ODT) at $199 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04017 | Henry Meds lists tirzepatide (compounded oral / ODT) at $349 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04018 | NexLife lists semaglutide (compounded microdose) at $110 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04019 | Shed lists semaglutide (compounded microdose) at $149 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04020 | Oak Longevity lists semaglutide (compounded injectable) at $133 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | third_party |
| EV-04021 | NexLife lists semaglutide (compounded injectable) at $145 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04022 | Found lists semaglutide (compounded injectable) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04023 | Shed lists semaglutide (compounded injectable) at $175 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04024 | Mochi Health lists semaglutide (compounded injectable) at $178 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04025 | Eden lists semaglutide (compounded injectable) at $198 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04026 | Noom Med lists semaglutide (compounded injectable) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04027 | TrimRx lists semaglutide (compounded injectable) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04028 | Enhance.MD lists semaglutide (compounded injectable) at $212 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04029 | bmiMD lists semaglutide (compounded injectable) at $289 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04030 | Henry Meds lists semaglutide (compounded injectable) at $297 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04031 | MEDVi lists semaglutide (compounded injectable) at $299 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04032 | NexLife lists semaglutide (compounded oral / ODT) at $165 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04033 | Henry Meds lists semaglutide (compounded sublingual) at $179 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04034 | Shed lists semaglutide (compounded sublingual) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04035 | Shed lists semaglutide (compounded sublingual) at $229 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04036 | Henry Meds lists semaglutide (compounded oral / ODT) at $249 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04037 | MEDVi lists semaglutide (compounded oral / ODT) at $369 per month, total including any required membership | Provider pricing dataset, July 2026 | never | Verification pending |
| EV-04038 | Found lists liraglutide (compounded injectable) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04039 | Henry Meds lists liraglutide (compounded injectable) at $179 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04040 | LillyDirect lists orforglipron (Foundayo) (brand oral, FDA-approved) at $149 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04041 | NovoCare Pharmacy lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $149 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04042 | LillyDirect lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $299 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04043 | NovoCare Pharmacy lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $349 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04044 | PlushCare lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $319 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04045 | WeightWatchers Clinic lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $323 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04046 | Hims lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $298 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04047 | Ro lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $348 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04048 | Found lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $447 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04049 | Eden lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $1794 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04050 | Hers lists tirzepatide (Mounjaro) (brand injectable, FDA-approved) at $2048 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-0108 | SURMOUNT-3 reported −18.4% additional weight reduction after a lifestyle lead-in versus +2.5% placebo | Wadden TA et al., Nature Medicine 2023 | 2026-07-24 | Provider-reported |
| EV-0109 | SURMOUNT-4 reported 5.5% further loss on continued treatment against 14.0% regain after withdrawal | Aronne LJ et al., JAMA 2024 | 2026-07-24 | Provider-reported |
| EV-0110 | SURPASS-2 reported HbA1c reductions of 2.01–2.30% with tirzepatide versus 1.86% with semaglutide 1 mg | Frías JP et al., N Engl J Med 2021 | 2026-07-24 | Provider-reported |
| EV-0111 | SURPASS-CVOT found tirzepatide non-inferior to dulaglutide for major adverse cardiovascular events | SURPASS-CVOT, 2024 | 2026-07-24 | Provider-reported |
| EV-0112 | SURMOUNT-1 publishes two estimands; the treatment-regimen figures are 15.0/19.5/20.9% and the efficacy figures are 16.0/21.4/22.5% | Jastreboff AM et al., N Engl J Med 2022 | 2026-07-24 | Provider-reported |
| EV-0501 | The Federation of State Medical Boards maintains a public directory of every state medical board | FSMB — Contact a State Medical Board | 2026-07-24 | Verified |
| EV-0502 | The National Association of Boards of Pharmacy maintains a public directory of state boards of pharmacy | NABP — Contact Your Board | 2026-07-24 | Verified |
| EV-0113 | Orforglipron (Foundayo) was FDA-approved on 1 April 2026 for chronic weight management, with reported mean weight reduction of approximately 11% to 12.4% at the highest dose over 72 weeks | FDA approves Lilly's Foundayo (orforglipron) | 2026-07-24 | Provider-reported |
| EV-0114 | OASIS 4 reported 13.6% mean weight reduction on the treatment-policy estimand and 16.6% among adherent participants, against 2.2% and 2.7% with placebo | Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 2025;393(11):1077-1087 | 2026-07-24 | Verified |
| EV-0115 | The Wegovy pill (oral semaglutide 25 mg) was FDA-approved on 22 December 2025 for weight management and for reducing the risk of major adverse cardiovascular events | Novo Nordisk: Wegovy pill approved in the US as first oral GLP-1 for weight management | 2026-07-24 | Verified |
| EV-0116 | LillyDirect self-pay pricing for Foundayo runs $149 to $349 by dose, with $299 on the top two doses when timely refill requirements are met; $25 per month with an eligible commercial savings card and $50 for eligible Medicare Part D patients from 1 July 2026 | FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity | 2026-07-24 | Provider-reported |
| EV-0601 | FDA states that registration as an outsourcing facility means only that the agency has received the required information. It does not mean the facility is making FDA-approved drugs, and it does not mean the facility is in compliance with CGMP requirements or the other conditions of section 503B | Questions and Answers: Outsourcing Facility Registration | 2026-07-24 | Verified |
| EV-0602 | FDA maintains a public register of outsourcing facilities and a searchable Outsourcing Facility Product Report database covering the last four reporting periods | Information for Outsourcing Facilities | 2026-07-24 | Verified |
| EV-0603 | Section 503B was created by the Drug Quality and Security Act, signed into law on 27 November 2013 | Information for Outsourcing Facilities — Drug Quality and Security Act | 2026-07-24 | Verified |
| EV-0604 | FDA's registration guidance for outsourcing facilities is issued under docket FDA-2013-N-1429 | Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B | 2026-07-24 | Verified |
| EV-0605 | FDA's 2019 guidance interpreting clinical need for the 503B bulks list states that clinical need is distinct from supply constraints or cost considerations | FDA Proposes to Exclude GLP-1 Receptor Agonists from the 503B Bulks List — analysis | 2026-07-24 | Provider-reported |
| EV-0606 | PCAB accreditation is administered through ACHC | 503A vs 503B compounding pharmacy — industry reference | 2026-07-24 | Provider-reported |
| EV-0607 | Reporting indicates FDA issued warning letters to approximately 30 telehealth firms over claims that compounded GLP-1s are identical to branded drugs, with 50 or more warning letters to compounders and distributors during 2025 | FDA Proposes to Exclude GLP-1s From 503B Bulk List | 2026-07-24 | Provider-reported |
| EV-0608 | Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at levels up to 86% | FDA Proposes to Exclude GLP-1s From 503B Bulk List | 2026-07-24 | Provider-reported |
| EV-0701 | The Zepbound label directs starting at 2.5 mg once weekly for 4 weeks, increasing to 5 mg, then increasing in 2.5 mg increments no sooner than every 4 weeks, to a maximum of 15 mg once weekly | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0702 | The label states the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0703 | The recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly. 7.5 mg and 12.5 mg are titration steps, not recommended maintenance dosages | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0704 | Zepbound carries a boxed warning for thyroid C-cell tumours observed in rats. Human relevance has not been determined. It is contraindicated in personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2, and in known serious hypersensitivity to tirzepatide or its excipients | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0705 | The label states that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0706 | Zepbound is indicated both for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0707 | Zepbound is supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, administered once weekly at any time of day with or without meals, into the abdomen, thigh or upper arm with site rotation | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0708 | In SURMOUNT-1, discontinuation due to an adverse event ranged from 4.3% to 7.1% across tirzepatide doses against 2.6% with placebo, and 50% and 57% of the 10 mg and 15 mg groups achieved 20% or greater weight reduction against 3% with placebo | Tirzepatide prescribing guide | 2026-07-24 | Provider-reported |
| EV-0801 | FDA issued 25 warning letters on 16 June 2026 to telehealth companies alleging false or misleading website claims about compounded semaglutide, tirzepatide and, in one case, liraglutide | FDA takes aim at misleading online claims for compounded GLP-1 drugs | 2026-07-24 | Provider-reported |
| EV-0802 | FDA issued more than 55 warning letters on 16 September 2025 to online sellers of compounded GLP-1s citing misleading direct-to-consumer advertising | FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown | 2026-07-24 | Provider-reported |
| EV-0803 | FDA issued 30 warning letters to telehealth companies in early 2026 threatening legal action without further notice; Commissioner Makary described it as a new era of enforcement | FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters | 2026-07-24 | Provider-reported |
| EV-0804 | On 6 February 2026 FDA announced it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products | FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs | 2026-07-24 | Provider-reported |
| EV-0805 | The FDA drug shortage record shows tirzepatide injection determined resolved on 2 October 2024; on 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation, and on 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA | FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | 2026-07-24 | Verified |
| EV-0806 | FDA set 22 May 2025 as the date until which it did not intend to take action against outsourcing facilities for violations depending on semaglutide injection's inclusion on the shortage list | FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | 2026-07-24 | Verified |
| EV-0807 | As of early 2025 FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from multidose vials, some requiring hospitalisation | FDA Moves to Permanently Close the Door on Compounded GLP-1s | 2026-07-24 | Provider-reported |
| EV-0808 | A 2026 study found that when tirzepatide is compounded with vitamin B12 the two substances can chemically bond, forming a molecule not present in the FDA-approved product. Compounders commonly add B12, B6, niacinamide, glycine or carnitine, combinations largely untested in clinical trials | Compounded GLP-1s: Why doctors worry and the FDA is cracking down | 2026-07-24 | Provider-reported |
| EV-0809 | TrumpRx launched on 5 February 2026 advertising direct access to lower-cost FDA-approved GLP-1s, listing semaglutide tablets at $149 to $299, semaglutide injections at $199 to $349 and tirzepatide injections at $299 to $449 | FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown | 2026-07-24 | Provider-reported |
| EV-0810 | The FDA Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review BPC-157, TB-500 and five other peptides for the 503A compounding list; briefing documents posted 30 June 2026 recommended against adding them | GLP-1 and peptide news digest | 2026-07-24 | Provider-reported |
| EV-0811 | Sandoz and Amneal filed abbreviated new drug applications for generic tirzepatide in 2026; Eli Lilly patents are reported to run to 2036 | Generic Tirzepatide: FDA Review and Patent Timeline | 2026-07-24 | Provider-reported |
| EV-0812 | STEP UP reported semaglutide 7.2 mg producing 20.7% weight loss, narrowing the gap with tirzepatide | STEP UP trial digest | 2026-07-24 | Provider-reported |
| EV-0813 | REIMAGINE 2 reported CagriSema reducing HbA1c 1.91 points more than semaglutide alone with 14.2% weight loss in 2,728 adults with type 2 diabetes | REIMAGINE 2 digest | 2026-07-24 | Provider-reported |
| EV-0814 | SOUL reported oral semaglutide reducing major adverse cardiovascular events by 14% and heart failure events by 22% in 9,647 high-risk patients with type 2 diabetes | SOUL trial digest | 2026-07-24 | Provider-reported |
| EV-0815 | EVOKE and EVOKE+ enrolled 3,808 participants over two years and found oral semaglutide made no difference to Alzheimer's disease progression | EVOKE trials digest | 2026-07-24 | Provider-reported |
| EV-0816 | Novo Nordisk reported the Wegovy pill surpassing three million prescriptions in just over five months from its January 2026 launch | FDA approves Novo Nordisk's Wegovy pill | 2026-07-24 | Provider-reported |
| EV-0901 | The Interstate Medical Licensure Compact affirms that the practice of medicine occurs where the patient is located at the time of the physician-patient encounter, and that a physician licensed via the compact is under the jurisdiction of the medical board in the state where the patient is located | Interstate Medical Licensure Compact states list and guide | 2026-07-24 | Provider-reported |
| EV-0902 | The IMLC is an expedited pathway to obtaining multiple separate state licences, not a single multistate licence. Each state continues to issue, renew and regulate its own licence | Telehealth Licensure 2025-2026: Cross-State Practice | 2026-07-24 | Provider-reported |
| EV-0903 | The IMLC reports 44 member states plus the District of Columbia and Guam as of 2026, with participation levels differing between members | IMLC providing expedited licensure in 44 states in 2026 | 2026-07-24 | Provider-reported |
| EV-0904 | The Nurse Licensure Compact is a multistate licence, distinct from the IMLC. Source counts differ: one lists 41 member states as of June 2026, another 43 jurisdictions in the enhanced compact as of April 2026 | Nurse Licensure Compact member states | 2026-07-24 | Provider-reported |
| EV-0905 | Advanced Practice Registered Nurses are covered by the APRN Compact and physician assistants by the PA Licensure Compact, which are separate from the IMLC | Interstate Medical Licensure Compact: What It Means for You | 2026-07-24 | Provider-reported |
| EV-1001 | SYNERGY-NASH was a phase 2 dose-finding trial of tirzepatide in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis, published as Loomba R et al., N Engl J Med 2024;391(4):299-310, registry NCT04166773 | Study Details NCT04166773 — ClinicalTrials.gov | 2026-07-24 | Verified |
| EV-1002 | Secondary sources report materially different MASH resolution rates for the 15 mg arm of SYNERGY-NASH: one gives 73.3% against 13.2% placebo, another 62% against 10% placebo | Conflicting secondary coverage of SYNERGY-NASH | 2026-07-24 | Provider-reported |
| EV-1003 | Tirzepatide is under evaluation for chronic kidney disease and has no completed dedicated kidney outcomes trial. Semaglutide's kidney outcomes evidence comes from the FLOW trial | Tirzepatide Shows Efficacy Resolving MASH — indications under evaluation | 2026-07-24 | Provider-reported |
| EV-1004 | A phase 3 programme, SYNERGY-OUTCOMES, launched in late 2025 with completion targeted for 2032 | GLP-1s and fatty liver disease — pipeline summary | 2026-07-24 | Provider-reported |
| EV-1101 | NexLife states that it serves patients nationwide across all 50 states | NexLife — tirzepatide plans | 2026-07-11 | Provider-reported |
| EV-1201 | Reporting states Embody keeps its entry price low — tirzepatide injections start at $149 for the first month — but refills then move to standard ongoing pricing of $399 per month, so it is not a flat-rate programme | Best Compounded Tirzepatide Providers (2026) | 2026-07-24 | third_party |
| EV-1202 | Embody's advertised tirzepatide starting rate has been reported at $99, $119, $129 and $149 across sources published within roughly two months, described in one as a promotional Summer Start rate that rises with dose and plan length | Embody Tirzepatide Ranked 2026 | 2026-07-24 | third_party |
| EV-1203 | Yucca Health's $146 monthly figure is its compounded semaglutide rate; its compounded tirzepatide is reported at $258 per month on a six-month commitment | Cheapest Tirzepatide in 2026 | 2026-07-24 | third_party |
| EV-1204 | TrimRx compounded tirzepatide is reported at $349 per month with flat pricing as the dose escalates; a separate source reports $449 per month standard with a $279 first-month rate on some monthly plans | How Much Does TrimRx Cost? Complete 2026 Pricing Guide | 2026-07-24 | Provider-reported |
| EV-1205 | Compounded tirzepatide pricing is reported to range from $99 per month at starter doses to over $300 at full therapeutic doses depending on the provider's dose-tiering model, and many dose-tiered providers charge their highest prices at the 10 mg and 15 mg doses where SURMOUNT-1 showed the largest reductions | Cheapest Tirzepatide Providers 2026 | 2026-07-24 | Provider-reported |
| EV-1206 | Reported dose-escalation behaviour: SkinnyRx rises from $129 toward $299 at higher tirzepatide doses; ShedRx from $199 toward $299; MEDVi from $179 to $299 after month one | Cheapest Compounded Tirzepatide Online: 6 Verified Programs Compared | 2026-07-24 | third_party |
| EV-1301 | On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157, KPV and TB-500 for the 503A bulks list, and 7-5 with two abstentions for MOTS-c, overriding FDA staff reviewers who had recommended against all seven substances under review | FDA advisory committee backs two controversial peptides | 2026-07-25 | Verified |
| EV-1302 | The committee's votes are non-binding. FDA makes the final determination through formal notice-and-comment rulemaking, and three distinct legal events are routinely conflated: removal from Category 2, a PCAC recommendation, and actual placement on the Category 1 compoundable list, which commonly requires 8 to 12 months | FDA Panel Votes to Loosen Restrictions for Four Peptides | 2026-07-25 | Verified |
| EV-1303 | FDA staff reviewers recommended against all seven peptides under review. For TB-500 they reported being unable to identify a single human clinical study. FDA's briefing package stated a lack of evidence to support the effectiveness of BPC-157 as a treatment for ulcerative colitis | FDA committee recommends looser restrictions for several peptides | 2026-07-25 | Verified |
| EV-1304 | On the BPC-157, KPV and TB-500 votes, all eight of the committee's newly added temporary members voted in favour; six other members voted against and one abstained. The committee has faced scrutiny over members with conflicts of interest | FDA to vote on peptide compounding: What to know | 2026-07-25 | Provider-reported |
| EV-1305 | In 2023 the FDA reviewed a batch of popular peptides and declined to add them to the 503A list, stating they may present significant safety risks. That decision placed BPC-157, TB-500 and others outside the sanctioned pharmacy pathway | FDA Panel Backs All 4 Peptides — regulatory background | 2026-07-25 | Provider-reported |
| EV-1306 | The committee met again on 24 July 2026 to consider emideltide (delta sleep-inducing peptide), epitalon and semax | July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee | 2026-07-25 | Verified |
| EV-1401 | On 24 July 2026 the committee recommended epitalon for insomnia and semax for cerebral ischemia, migraine and trigeminal neuralgia, and voted against emideltide for opioid withdrawal, chronic insomnia and narcolepsy by 6-7 with one abstention. Across the two-day meeting six of seven peptides were recommended | FDA advisory committee backs two more peptides, rejects one for compounding list | 2026-07-25 | Verified |
| EV-1402 | All seven substances were removed from the FDA's Category 2 list on 23 April 2026, which is what made them eligible for this review. The July votes were therefore about opening a new lawful compounding channel, not about closing an existing one | Peptide docket FDA-2025-N-6895, Category 2 reclassification | 2026-07-25 | Provider-reported |
| EV-1403 | Each substance was reviewed against a specific proposed use rather than for blanket compounding: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, emideltide for opioid withdrawal, insomnia and narcolepsy, semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia | FDA to vote on peptide compounding: What to know | 2026-07-25 | Verified |
| EV-1404 | Under section 503A a compounded drug is exempt from FDA approval and manufacturing requirements only if the bulk substance complies with a USP monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List | Section 503A bulk substance conditions | 2026-07-25 | Verified |
| EV-1405 | All seven substances lack the large, well-controlled human trials required to establish safety and effectiveness for drug approval, with the level of evidence varying between them | FDA advisers vote to ease peptide restrictions, despite agency concerns | 2026-07-25 | Verified |
| EV-1501 | A 2026 study found that when tirzepatide is compounded with vitamin B12, the two substances can chemically bond, forming a new molecule not found in the FDA-approved drug | Compounded GLP-1s: Why doctors worry and the FDA is cracking down | 2026-07-26 | Verified |
| EV-1502 | Many compounders add extra ingredients to differentiate their products from FDA-approved GLP-1s, most commonly vitamin B12 but also B6, niacinamide, glycine or carnitine, none of which has proven benefit for weight loss or diabetes management, and these combinations are largely untested in clinical trials | Compounded GLP-1s: Why doctors worry and the FDA is cracking down | 2026-07-26 | Verified |
| EV-1503 | Some compounders use chemically distinct salt forms such as semaglutide sodium rather than the base molecule; these salt forms have not been proven safe and effective in humans or approved by the FDA, and effectiveness can differ because of the salt form difference | Compounded GLP-1s: Why doctors worry and the FDA is cracking down | 2026-07-26 | Verified |
| EV-1504 | On 29 January 2026 the MHRA updated product information for GLP-1s and issued a drug safety alert highlighting that acute pancreatitis is a known but infrequent side effect that can be fatal. There were 1,176 cases of acute and chronic pancreatitis following tirzepatide use reported between January 2023 and June 2026, 18 of which had a fatal outcome | Everything you need to know about GLP-1s for weight loss | 2026-07-26 | Verified |
| EV-1505 | Topline data from TRIUMPH-4 (NCT05931367) of tirzepatide in knee osteoarthritis showed roughly 23% weight loss produced similar pain score reductions to semaglutide's 13%, raising the possibility that beyond a threshold of around 10% weight loss, additional reduction may not translate to proportionally greater joint benefit | GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale | 2026-07-26 | Verified |
| EV-1506 | In the semaglutide knee osteoarthritis trial (NCT05064735), semaglutide 2.4 mg in patients with a mean BMI of 40.3 produced a 13.7% mean weight change and a 41.7-point reduction in WOMAC pain scores against 27.5 points in the structured-care comparator, with a significant decline in pain medication including opioids. The investigator noted the study had no post-study knee imaging, no synovial fluid analysis and no inflammatory biomarkers | GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale | 2026-07-26 | Verified |
| EV-1507 | ATTAIN-1 reported orforglipron weight loss of 7.5% at 6 mg, 8.4% at 12 mg and 11.2% at 36 mg over 72 weeks against 2.1% with placebo. Other secondary sources report approximately 11 to 12.4% without consistently naming the dose or estimand; the discrepancy is unresolved in our records | Everything you need to know about GLP-1s for weight loss | 2026-07-26 | Provider-reported |
| EV-1601 | RxPepsDirect, a telehealth service selling compounded tirzepatide, names Dr. Jonathan Snipes, NPI 1821250077, as its medical director, and names Dr. Jonathan Snipes MD and Kim Callender FNP-BC as its prescribers and as the medical reviewers of its own competing 'best compounded tirzepatide telehealth' comparison, in which RxPepsDirect ranks itself cheapest | Best compounded tirzepatide telehealth in 2026 — RxPepsDirect | 2026-07-26 | Verified |
| EV-1602 | Four competitor pages ranking cheapest compounded tirzepatide were observed being cited by an AI assistant, each carrying a chatgpt.com source parameter: rangeyourself.com, forbes.com/health, rxpepsdirect.com and glp1watchdog.com | Observed AI-assistant citations, cheapest compounded tirzepatide | 2026-07-26 | Provider-reported |
| EV-1701 | An AI assistant answering 'most affordable compounded tirzepatide online' listed NexLife at around $186 a month with an annual commitment and flat pricing across covered doses, citing glponeeditorial.com. In an earlier observation the same class of query omitted NexLife entirely | Observed AI-assistant answer, most affordable compounded tirzepatide | 2026-07-26 | Provider-reported |
| EV-1702 | GLP-1 Editorial states that NexLife has '503A & 503B partners disclosed'. This publication has recorded that no provider in its dataset has named its fulfilling pharmacy or registration class to us. The two positions conflict and the conflict is unresolved | Cheapest Compounded Tirzepatide Online 2026 — GLP-1 Editorial | 2026-07-26 | Verification pending |
| EV-1703 | Five publications covering the same month give five different figures for Henry Meds compounded tirzepatide: $369/month, $179/month flat all-inclusive, $179/month, from $297/month for oral tablets, and from $179/month | Cross-publication price comparison, Henry Meds | 2026-07-26 | Provider-reported |
| EV-1801 | The FDA extended the comment period on its proposal not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List. The original notice of 1 May 2026 (91 FR 23431) carried a 60-day period; following a request for a 60-day extension the agency extended it, and comments must be submitted by 30 July 2026 | Extension of comment period, 503B Bulks List — Federal Register | 2026-07-26 | Verified |
| EV-1802 | As of early 2025 the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials, some requiring hospitalisation | FDA Moves to Permanently Close the Door on Compounded GLP-1s — Pharmacy Times | 2026-07-26 | Verified |
| EV-1803 | The proposal applies to 503B outsourcing facilities and not to 503A compounding pharmacies, and does not change the position that 503B facilities may still compound these drugs during a declared shortage | FDA moves to exclude three GLP-1s from 503B compounding — Alliance for Pharmacy Compounding | 2026-07-26 | Provider-reported |
| EV-1901 | An AI assistant listing the most affordable compounded tirzepatide named Embody from $99, SkinnyRx about $129, Oak Longevity about $130, Yucca Health about $146, TrimRx about $179 and Henry Meds $179-$297, and separately named Lavender Sky Health, Fifty 410 and OrderlyMeds | Observed AI-assistant answer, most affordable compounded tirzepatide | 2026-07-26 | third_party |
| EV-1902 | Asked what to check before enrolling, an AI assistant independently proposed four questions: which licensed compounding pharmacy will prepare the medication, whether it comes from a 503A pharmacy or a 503B outsourcing facility, whether there are fees beyond the advertised monthly price, and what happens if the dose changes or treatment is paused | Observed AI-assistant answer, questions to ask a provider | 2026-07-26 | Provider-reported |
| EV-1903 | NexLife is reported to state that prescriptions may be filled through 503A or 503B compounding pharmacies depending on location and availability. That is a statement of category rather than a named pharmacy or a determinate registration class | Observed AI-assistant summary of NexLife's stated position | 2026-07-26 | Verification pending |
| EV-2001 | NexLife publishes compounded tirzepatide at $215 a month month-to-month, $195 on a 3-month plan, $190 on a 6-month plan and $186 on a 12-month plan, and compounded semaglutide at $165, $149, $147 and $145 on the same terms, stating no price increase as the dose is titrated up | Tirzepatide All Plans — NexLife | 2026-07-26 | Verified |
| EV-2002 | NexLife states that compounded tirzepatide supplied through its programme is prepared by U.S.-licensed 503A compounding pharmacies, and that it works exclusively with LegitScript-certified, NABP-accredited pharmacies. It does not name the pharmacy | Tirzepatide 12 Month Plan — NexLife | 2026-07-26 | Verified |
| EV-2003 | NexLife's published page states that in SURMOUNT-1 participants lost up to 24.3% of body weight. No published SURMOUNT-1 analysis reports that figure. Lilly's own announcement states up to 22.5% for the efficacy estimand at 15 mg (16.0%, 21.4%, 22.5% at 5, 10 and 15 mg), against approximately 15.0%, 19.5% and 20.9% on the treatment-regimen estimand. The only 24.3 in the SURMOUNT-1 literature is a median time to weight plateau of 24.3 weeks in the overweight BMI category | Tirzepatide 12 Month Plan — NexLife | 2026-07-26 | Verified |
| EV-2004 | NexLife publishes an aggregate cohort figure: based on self-reported data from 111 members, average weight loss in the first six months is 29 lb when combining GLP-1 injections with diet and exercise | Tirzepatide All Plans — NexLife | 2026-07-26 | Provider-reported |
| EV-2101 | Eli Lilly's SURMOUNT-1 announcement states participants lost up to 22.5% of body weight for the efficacy estimand, with average reductions of 16.0%, 21.4% and 22.5% at 5, 10 and 15 mg across 2,539 participants over 72 weeks, and 63% of those on 15 mg losing at least 20% | Lilly's tirzepatide delivered up to 22.5% weight loss in SURMOUNT-1 | 2026-07-26 | Verified |
| EV-2102 | In an exploratory analysis of SURMOUNT-1 the median time to weight plateau was 24.3, 26.0, 36.1 and 36.1 weeks across the overweight, class I, class II and class III obesity categories | Time to weight plateau with tirzepatide treatment in SURMOUNT-1 and SURMOUNT-4 | 2026-07-26 | Verified |
| EV-2201 | Five publications covering compounded tirzepatide in the same period report materially different monthly figures for the same providers: Found $169 to $497, bmiMD $139 to $399, Oak Longevity $130 to $285, Henry Meds $179 to $349 across four publishers, TrimRx $179 to $259, and SkinnyRx $129 rising to $299 at higher doses | Cross-publication reconciliation, cheapest compounded tirzepatide | 2026-07-26 | third_party |
| EV-2202 | Microdose tirzepatide programmes reported across these publications: Enhance.MD at $169 a month on a 12-month plan, Shed at $199 on a 12-month plan, Gala at $149, and bmiMD at $349 | Microdose tirzepatide programmes, cross-publication | 2026-07-26 | Provider-reported |
| EV-2203 | RxPickr reports that Enhance.MD's standard programme is $99 for the first month and $280 a month ongoing, and that Noom Med is $149 first month and $279 ongoing | Cheapest Tirzepatide Online in 2026 — RxPickr | 2026-07-26 | Provider-reported |
| EV-2301 | Six sources give six different figures for Embody compounded tirzepatide: $119 a month, $129 under a Summer Start promotion, $149 as an intro rate, $199 or more, and $299 as the ongoing rate after the first month. Several state explicitly that the low figure is promotional and rises to $299 after month one. The $99 figure widely republished is a semaglutide rate, not tirzepatide | Cross-source check, Embody compounded tirzepatide pricing | 2026-07-27 | third_party |
| EV-2302 | This publication republished monthly figures for ten providers taken from competitor comparison pages rather than from the providers' own sites, and labelled them provider-reported. They were third-party claims that had not been confirmed at source | Internal audit of price provenance | 2026-07-27 | Verified |
| EV-2401 | Henry Meds compounded tirzepatide is reported at $179 a month flat by four publications, at $199 by another, at about $297 introductory rising to $429-$549 at maintenance by another, and at $1,047 for a three-month oral supply by Forbes Health. One source that examined the pricing states the $179 headline applies to liraglutide or a 12-month prepay rather than injectable tirzepatide, and that dose escalation adds about $100 a month per tier | Cross-source check, Henry Meds compounded tirzepatide pricing | 2026-07-27 | third_party |
| EV-2402 | Hims is reported to have stopped offering tirzepatide following a March 2026 settlement with Novo Nordisk | Henry Meds Reviews 2026 — PeptidesExplorer | 2026-07-27 | third_party |
| EV-2403 | TrimRx, itself a telehealth provider, publishes that the lowest legitimate compounded tirzepatide prices in 2026 are around $249-$329 a month for starter doses and $349-$549 for maintenance, and that pricing below $200 a month for tirzepatide maintenance is a red flag for bait-and-switch pricing or non-legitimate sourcing | Cheapest Compounded Tirzepatide Providers 2026 Ranked — TrimRx | 2026-07-27 | third_party |
| EV-2404 | An independent review states it verified Henry Meds and parent company Adonis Health Inc. against the FDA warning-letter database on 21 April 2026 and found no warning letter | Henry Meds Review 2026 — Healthy Meals Incentives | 2026-07-27 | third_party |
| EV-2501 | The FDA has issued three major waves of warning letters to telehealth companies over compounded GLP-1 marketing in under a year: roughly 80 warning letters and 40 untitled letters in September 2025, 30 warning letters on 20 February 2026 announced on 3 March, and 25 warning letters dated 8 June 2026 and posted on 16 June. Recipients are given 15 business days to correct the violations | FDA's Focus Returns to Compounding and Telehealth | 2026-07-27 | Verified |
| EV-2502 | The enforcement framework is misleading net impression: the FDA assesses whether marketing taken as a whole could cause a consumer to believe a compounded product is FDA-approved, FDA-reviewed, or equivalent in any way to an approved drug, whether stated explicitly or implied | FDA's Focus Returns to Compounding and Telehealth | 2026-07-27 | Verified |
| EV-2503 | The FDA has published a GLP-1 webpage stating its position that retatrutide and cagrilintide may not be used in compounding, alongside guidance on import alerts for active ingredients with quality concerns, dosing concerns, counterfeit versions of brand-name GLP-1s, and adverse event reporting | FDA's Focus Returns to Compounding and Telehealth | 2026-07-27 | Verified |
| EV-2504 | Among the June 2026 letters, Altru Telehealth was cited for claims including FDA approved active ingredient, same results, and FDA approved compounding pharmacy, and for website language stating that a compounded semaglutide included a body safe vitamin such as B12. Glow Medispa and Ready Med were cited for product images whose labels implied the telehealth company was the compounder when it was not | FDA Posts 25 Warning Letters Over Compounded GLP-1 Marketing Claims | 2026-07-27 | Verified |
| EV-2505 | On 9 February 2026 Novo Nordisk sued Hims & Hers for infringing US Patent No. 8,129,343 with its compounded semaglutide products, alleging the company continued to mass-compound injectable versions made with inauthentic active ingredient | FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown | 2026-07-27 | Verified |
| EV-2601 | In April 2025 Novo Nordisk notified the FDA that several hundred units of Ozempic injection 1 mg had been distributed outside its authorised supply chain. The counterfeit product carries lot number PAR0362, which is an authentic lot number, coupled with a serial number beginning with the eight digits 51746517. The product is counterfeit only when the lot number appears together with those eight digits. The FDA seized the identified products on 9 April 2025 | FDA warns consumers not to use counterfeit Ozempic | 2026-07-27 | Verified |
| EV-2602 | In December 2025 the FDA seized dozens of units of counterfeit Ozempic injection 1 mg labelled with lot number PAR1229, also an authentic lot number. The counterfeit can be identified by the position of the EXP/LOT text on the pen label: on the counterfeit it sits to the left of the expiration date and lot number, while on an authentic pen it sits above them | FDA warns consumers not to use counterfeit Ozempic | 2026-07-27 | Verified |
| EV-2603 | Analysis of the seized products found the needles were also counterfeit, so their sterility cannot be confirmed, presenting an increased risk of infection. Other confirmed counterfeit components were the pen label, the accompanying healthcare professional and patient information, and the carton. The FDA and Novo Nordisk could not confirm the identity, quality or safety of the drug itself | FDA warns consumers not to use counterfeit Ozempic | 2026-07-27 | Verified |
| EV-2604 | The FDA is aware of five adverse events from the PAR1229 lot, none serious, and consistent with known common adverse reactions to authentic Ozempic: nausea, vomiting, diarrhoea, abdominal pain and constipation | FDA warns consumers not to use counterfeit Ozempic | 2026-07-27 | Verified |
| EV-2605 | Novo Nordisk states that Ozempic 1 mg products acquired through its Patient Assistance Program are genuine and not counterfeit, notwithstanding the lot number | Dozens of Counterfeit Ozempic Seized by the FDA | 2026-07-27 | Verified |
| EV-2606 | Both confirmed counterfeit Ozempic incidents involved product that had entered the legitimate United States drug supply chain, meaning it reached patients through licensed retail pharmacies | FDA warns consumers not to use counterfeit Ozempic | 2026-07-27 | Verified |
| EV-2701 | Zepbound single-dose vials through the LillyDirect Self Pay Journey Program are $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5 and 15 mg. Lilly announced these reductions on 1 December 2025, cutting 2.5 mg from $349, 5 mg from $499 and the higher doses from $499 | Lilly lowers the price of Zepbound single-dose vials | 2026-07-27 | Verified |
| EV-2702 | LillyDirect states that regular prices apply if the prescription is not refilled within 45 days: $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg | Authentic Zepbound shipped to you — LillyDirect | 2026-07-27 | Verified |
| EV-2703 | LillyDirect's own product page states that 2.5 mg is a starting dose and is not approved as a maintenance dose | Authentic Zepbound shipped to you — LillyDirect | 2026-07-27 | Verified |
| EV-2704 | The $449 purchase offer applies automatically on a first purchase of the 7.5, 10, 12.5 or 15 mg single-dose vial or KwikPen from 23 February 2026 | Coverage, Affordability and Savings — Zepbound | 2026-07-27 | Verified |
| EV-2705 | A TrumpRx programme is reported to have launched in early February 2026 offering Zepbound at around $350 a month without insurance, competing directly with LillyDirect self-pay pricing | LillyDirect Zepbound pricing | 2026-07-27 | third_party |
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Verified entries | 70 | 95% |
| Pending | 4 | 5% |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | The claim | Written as it appears on the page, not paraphrased. |
| 2 | The source | Title, URL and type. The thing itself, not coverage of it. |
| 3 | The capture | Date, reviewer, and a stored screenshot or archive. |
| 4 | The strength | Primary, secondary, provider-reported or inferred. |
| 5 | The next review | A date after which the entry is marked outdated automatically. |
Take the data with youCC BY 4.0 with attribution
Suggested citation: Tirzepatide Ranked, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.
Related on this site
- Open data libraryData
- GLP-1 Provider Pricing DatasetData
- Methodology and Dataset ChangelogData
- GLP-1 Data API DocumentationData
- The 100-point rubricCore & Trust
- Cost calculatorTools
- Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Advertising and Sponsored Content PolicyCore & Trust
Related coverage
- GLP-1 Provider Pricing Dataset
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week
- FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss
- GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4%
- Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036
- A Major Telehealth Platform Withdrew a Compounded Copy of the Wegovy Pill Under Legal Threat
- Medicare GLP-1 Bridge Opens: $50 a Month for Eligible Part D Enrollees
Cite this pageCC BY 4.0
Tirzepatide Ranked. “Provider and Study Source Ledger.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/data/source-ledger/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.
Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.